Journal of Controlled Release : Official Journal of the Controlled Release Society
Overview
The Journal of Controlled Release is the official publication of the Controlled Release Society. It is a leading interdisciplinary journal that focuses on the science and technology of controlled release systems. The journal publishes original research articles, reviews, and commentaries covering various aspects of drug delivery, nanomedicine, biomaterials, and pharmaceutical sciences. With its broad scope and high-quality content, the journal serves as a valuable resource for researchers, scientists, and professionals in the field of controlled release.
Details
Details
Abbr.
J Control Release
Start
1984
End
Continuing
Frequency
Twenty four no. a year, 2001-
p-ISSN
0168-3659
e-ISSN
1873-4995
Country
Netherlands
Language
English
Specialty
Pharmacology
Metrics
Metrics
h-index / Ranks: 172
313
SJR / Ranks: 1049
2157
CiteScore / Ranks: 487
17.10
JIF / Ranks: 410
10.8
Recent Articles
1.
Zhou H, Yang Z, Jin G, Wang L, Su Y, Liu H, et al.
J Control Release
. 2025 Mar;
:113628.
PMID: 40088979
Chemotherapy remains a vital component of cancer treatment, with combination therapy widely used in clinical practice to overcome the limitations of single-drug administration. However, challenges persist including pharmacokinetic discrepancies among...
2.
Ljubimov V, Sun T, Wang J, Li L, Wang P, Ljubimov A, et al.
J Control Release
. 2025 Mar;
:113611.
PMID: 40088978
Primary Central Nervous System Lymphoma is an aggressive central nervous system neoplasm with poor response to pharmacological treatment, partially due to insufficient drug delivery across blood-brain barrier. In this study,...
3.
Liu C, Guo L, Yue P, Xie D, Gao J, Li Y, et al.
J Control Release
. 2025 Mar;
:113627.
PMID: 40088977
Developing antimicrobial therapies not rely on antibiotics is an expective way to resolve the threat of drug-resistant bacteria, such as photodynamic antimicrobial therapy (APDT). However, the main antibacterial species in...
4.
Coelho M, Quintas S, Sarmento B, de Wever O, Castro F
J Control Release
. 2025 Mar;
:113620.
PMID: 40088976
Extracellular vesicles (EVs) have emerged as a cell-free therapeutic approach, garnering increasing attention for their potential to enhance the safety and efficacy of immunotherapy. This interest is primarily driven by...
5.
Tang X, Deng J, He C, Xu Y, Bai S, Guo Z, et al.
J Control Release
. 2025 Mar;
:113629.
PMID: 40086761
Subunit vaccines are crucial in preventing modern diseases due to their safety, stability, and ability to elicit targeted immune responses. However, challenges in antigen and adjuvant design hinder their development....
6.
Gonzalez-Prada I, Barcelos A, Ribeiro A, Dion M, Magarinos B, Lapoujade C, et al.
J Control Release
. 2025 Mar;
:113615.
PMID: 40086760
Glioblastoma (GB) is a malignant brain tumor with low survival rates and a high recurrence ratio due to limited therapeutic arsenal. The repurposed drug disulfiram (DSF), approved for alcoholism treatment,...
7.
Wu T, Zhao P, Pan P, Zhao Z, Zhu Y, Cheng J
J Control Release
. 2025 Mar;
381:113618.
PMID: 40086759
Biofilms are complex bacterial communities that significantly hinder the treatment of chronic and recurrent infections by enhancing bacterial virulence and conferring resistance to antimicrobial therapies. To address this challenge, an...
8.
Boix-Montesinos P, Carrascosa P, Arminan A, Vicent M
J Control Release
. 2025 Mar;
:113584.
PMID: 40086758
Nanomedicines represent promising advanced therapeutics for the enhanced treatment of breast cancer, the primary cause of cancer-related deaths in women; however, the clinical translation of nanomedicines remains challenging. Advanced in...
9.
Spanoghe J, Wynendaele E, Vergaelen M, De Colvenaer M, Mariman T, Vonck K, et al.
J Control Release
. 2025 Mar;
:113626.
PMID: 40086757
Up to 30 % of epilepsy patients suffer from drug-resistant epilepsy (DRE). The search for innovative therapies is therefore important to close the existing treatment gap in these patients. The...
10.
Lee S, Kim B, Lee M, Kim D, Park S, Kim J, et al.
J Control Release
. 2025 Mar;
:113625.
PMID: 40081740
Traditional drug delivery systems for OA treatments face limitations due to rapid clearance within the joint and low biocompatibility. Moreover, the inflammation associated with OA exacerbates tissue damage and delays...